Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Prostatic Neoplasms 42Lung Neoplasms 39Leukemia, Myeloid, Acute 38Carcinoma, Non-Small-Cell Lung 33Neoplasm Metastasis 29Breast Neoplasms 27Myelodysplastic Syndromes 21Lymphoma, Large B-Cell, Diffuse 20Leukemia, Lymphocytic, Chronic, B-Cell 19Colorectal Neoplasms 18Pancreatic Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Triple Negative Breast Neoplasms 15Multiple Myeloma 15Ovarian Neoplasms 14Glioblastoma 14Squamous Cell Carcinoma of Head and Neck 13Carcinoma, Renal Cell 13Burkitt Lymphoma 13Urinary Bladder Neoplasms 10Mouth Neoplasms 10Melanoma 10Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Carcinoma, Hepatocellular 10Carcinoma 10Oropharyngeal Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Laryngeal Neoplasms 9Brain Neoplasms 9

Interventions

Rituximab 7zanubrutinib 6venetoclax 4ibrutinib 3Dexamethasone 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2Blood Specimen Collection 2Biopsy 2Bendamustine Hydrochloride 2pirtobrutinib 1obinutuzumab 1Positron-Emission Tomography 1Lenalidomide 1Exercise 1Diet 1CT-P10 1Bortezomib 1ARQ531 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Waldenstrom Macroglobulinemia × Specimen Handling × Clear all
NCT04840602 2026-06-03

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
92 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic

Phase 1 Recruiting
46 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmSarcoma

Blastic Plasmacytoid Dendritic Cell Neoplasm, Histiocytosis, Langerhans-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Erdheim-Chester Disease, Dendritic Cell Sarcoma, Interdigitating, Histiocytic Sarcoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡